CRISPR/Cas9: a powerful tool in colorectal cancer research

J Exp Clin Cancer Res. 2023 Nov 22;42(1):308. doi: 10.1186/s13046-023-02901-z.

Abstract

Colorectal cancer (CRC) is one of the most common malignant cancers worldwide and seriously threatens human health. The clustered regulatory interspaced short palindromic repeat/CRISPR-associate nuclease 9 (CRISPR/Cas9) system is an adaptive immune system of bacteria or archaea. Since its introduction, research into various aspects of treatment approaches for CRC has been accelerated, including investigation of the oncogenes, tumor suppressor genes (TSGs), drug resistance genes, target genes, mouse model construction, and especially in genome-wide library screening. Furthermore, the CRISPR/Cas9 system can be utilized for gene therapy for CRC, specifically involving in the molecular targeted drug delivery or targeted knockout in vivo. In this review, we elucidate the mechanism of the CRISPR/Cas9 system and its comprehensive applications in CRC. Additionally, we discussed the issue of off-target effects associated with CRISPR/Cas9, which serves to restrict its practical application. Future research on CRC should in-depth and systematically utilize the CRISPR/Cas9 system thereby achieving clinical practice.

Keywords: CRC; CRISPR/Cas9; Gene editing tool; Off-target; Precise medicine; Target therapy.

Publication types

  • Review

MeSH terms

  • Animals
  • CRISPR-Cas Systems*
  • Colorectal Neoplasms* / genetics
  • Colorectal Neoplasms* / therapy
  • Genetic Therapy
  • Humans
  • Mice
  • Oncogenes